



## BioInvent Interim Report 1 January – 30 June 2009

- Treatment of the first cohort of 100 patients is completed in the phase II study with product candidate TB-402, for the prevention of deep vein thrombosis (DVT). Recruitment of the second 100 patient cohort has been started.
- The phase I trial of BI-204 has been successfully completed. The product candidate to treat secondary cardiac events in patients with acute coronary syndrome was well tolerated. The drug is being co-developed with Genentech, Inc., a wholly-owned member of the Roche Group.
- Technology transfer under the terms of the alliance with Roche on product candidate TB-403 for the treatment of cancer has triggered a success fee of EUR 5 million to BioInvent and ThromboGenics.
- An application to initiate phase I trials of the product candidate BI-505 for the treatment of multiple myeloma has been submitted to the US Food and Drug Administration.
- Product candidate BI-505 has been granted orphan drug designation in Europe for the indication multiple myeloma. Equivalent status was previously granted in the US.
- Net revenues for January - June 2009: SEK 47.1 million (211.8 including initial milestone payment of 187.6 relating to TB-403).
- Current investments together with cash and bank as of 30 June 2009: SEK 150.5 million (121.7).
- Cash flow from current operations and investment activities for January – June 2009: SEK -61.9 million (-95.2).
- Loss after tax for January - June 2009 amounted to SEK -88.2 million (93.8) and the profit after tax per share was SEK -1.59 (1.68).

*BioInvent is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects mainly within the areas of thrombosis, cancer and atherosclerosis.*

### Comments by the CEO

We continue to make good progress in our projects. It is gratifying to see the rapid pace of enrolment of patients to the phase II clinical trial of TB-402, for the prevention of deep vein thrombosis (DVT). The first group of 100 patients has been enrolled and treated and we are already working on enrolling the next dose group, which will also include 100 patients. The study is being carried out on a total of 300 patients who have received an artificial knee joint. The purpose is to compare the effect of TB-402 with current standard treatment. TB-402 is administered once in conjunction with the surgical procedure, unlike current therapy which requires daily dosage for several weeks. The results from earlier studies show that TB-402 has prospects to be developed into a safe and well-controlled treatment for several medical conditions in which thrombosis prevention is of great importance.

The phase I programme of BI-204 has been successfully completed. The product candidate was found to be well tolerated. Pharmacokinetic results enables development of a product with a competitive dosing regimen. We expect the phase II programme to be in progress by year end.

An application to initiate clinical trials of BI-505 was submitted to the US Food and Drug Administration (FDA) in June. Earlier this year BioInvent met with the FDA to discuss various aspects of the upcoming clinical programme. The first indication for BI-505 will be the treatment of multiple myeloma, for which there is a significant need for effective new medications. The clinical programme will provide exposure in this important pharmaceutical market, while the company gains valuable experience from running clinical trials in the United States.

In conclusion these advances mean that we are well on the way to achieving the objectives that we set at the beginning of the year: to succeed in taking four projects to clinical trials, including three to clinical phase II trials.

## **Development projects**

BioInvent is currently running four projects in the development phase. In the development phase the safety profile of the product candidate is tested in animal models, before testing safety and efficacy in clinical trials.

### **Thrombosis (TB-402)**

TB-402 is a human antibody binding to Factor VIII. The antibody has shown a beneficial partial inhibition of Factor VIII, even when applied in excess dosage. This reduces the risk of undesirable bleedings. The objective is to initially develop a drug that prevents Deep Vein Thrombosis (DVT) following orthopaedic surgery. DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the US alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist. Patients undergoing hip replacement or knee surgery are particularly at risk of developing DVT and all patients are therefore treated with anticoagulants prophylactically in order to reduce the risks of blood clots. The project is carried out within the alliance with ThromboGenics.

Results from the Phase I trial show that TB-402 is both safe and well-tolerated. No serious adverse events related to TB-402 were reported. The pharmacokinetic analysis undertaken as part of the Phase I trial confirm a prolonged half-life of approximately three weeks, which will allow for single dose treatment in orthopaedic surgery patients and/or a once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as opposed to daily treatment with current anticoagulants. The pharmacodynamic analysis confirms that TB-402 achieves only partial inhibition of Factor VIII activity without the undesired effect of total inactivation. A stable long-acting anticoagulant effect based on partial Factor VIII inhibition could also be shown.

Additional studies have shown that the effect of TB-402 can be reversed by giving the target protein (Factor VIII) that blocks TB-402 and also that TB-402 is safe and well tolerated in patients that are given standard treatment (enoxaparin and warfarin) for deep vein thrombosis. The results show that TB-402 has prospects to be developed into a safe and well-controlled treatment for several medical conditions in which thrombosis prevention is of great importance.

Treatment of the first cohort of 100 patients is completed in the Phase II study, for the prevention of deep vein thrombosis (DVT), in patients who have received an artificial knee joint. Recruitment of the second 100 patient cohort has been started following the unanimous advice from the external efficacy and safety monitoring board to proceed using a higher dose of TB-402.

The Phase II trial, initiated in February 2009, is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The trial will enrol 300 patients in up to 36 centers in Europe. The objective of the study is to assess the safety and efficacy of the three escalating doses of TB-402.

### **Atherosclerosis (BI-204)**

The product candidate BI-204 targets oxidized forms of the LDL cholesterol (oxLDL). Links have been shown between oxidized forms of certain lipoproteins and the inflammatory processes that lead to plaque formation in the vessel walls. BI-204 has in preclinical studies reduced inflammatory processes and reduced plaque formation significantly. The results also show a considerable reduction in the size of existing plaques in animals treated with BI-204. Results supports that the mechanism behind BI-204 is a modulation of the inflammatory process resulting in a reduction of pro-inflammatory cells in treated

plaques, which in turn leads to a reduction in new plaque formation and the regression of existing plaques. It is being developed as a drug for the secondary prevention of cardiac events, such as heart attack or stroke, in high-risk patients. In a population-based, prospective, observational study of the risk of development of coronary artery disease (JAMA. 2008; 299 (19) 2287-2293) higher concentration of oxidized LDL was associated with increased incidence of metabolic syndrome overall, as well as its components of insulin resistance and hyperglycemia. These observations support the picture that oxidized LDL can be an important target structure for developing new medications to treat patients with type 2 diabetes and metabolic syndrome. BI-204 is developed in collaboration with Genentech, Inc, a wholly-owned member of the Roche Group.

The phase I programme has been successfully completed. BI-204 was well tolerated. Pharmacokinetic results showed the half-life was in the expected range for fully human antibodies. The Phase I study was a double-blind, within-group randomised dose-escalation trial testing both single and multiple doses of BI-204 administered either intravenously or subcutaneously. In total, 80 healthy male or female subjects with elevated levels of LDL cholesterol were included in the trial.

### Cancer (TB-403)

The product candidate TB-403, is a monoclonal antibody directed against placental growth factor, PIGF. TB-403 binds PIGF with high affinity and specificity and has been shown to inhibit tumour growth in animal models. TB-403 blocks tumour angiogenesis, the development of new blood vessels, which is required for tumour nutrient and oxygen supply supporting tumour growth. Angiogenesis is also required for disease progression and metastasis, the dissemination of the tumour to distal sites of the body.

The PIGF growth factor is secreted by tumours and is specifically over expressed in cancer and chronic inflammatory conditions. It affects the formation of new vessels in tissue that is under stress. PIGF is not required for survival of normal resting vasculature and blocking PIGF is expected to be relatively safe, because mice lacking PIGF are healthy and reproduce normally. Preclinical research has also shown that inhibition of PIGF does not induce resistance mechanisms because it does not induce "angiogenic rescue" mechanisms, whereby tumour expression of proangiogenic growth factors is upregulated that may enable escape from therapy. This angiogenic rescue phenomenon has been demonstrated with some angiogenesis inhibitors.

The first Phase I study in 16 healthy male subjects was successfully completed in June 2008 and showed that TB-403 is safe and well tolerated, with pharmacokinetic properties enabling it to be developed as a novel anti-cancer agent. The follow-up study is a study of tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer, and was started in June 2008. All patients have been included in the study.

### *Agreement with Roche*

In June 2008 BioInvent and partner ThromboGenics entered into a strategic license agreement with Roche for development and commercialisation of TB-403. Roche paid BioInvent and ThromboGenics an upfront payment of EUR 50 million in July 2008. In addition, BioInvent and ThromboGenics could potentially receive up to EUR 450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PIGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal.

Roche has a worldwide, exclusive license to develop and commercialise TB-403. BioInvent and ThromboGenics will retain co-promotion rights for the product in the Nordic, Baltic and Benelux regions. Roche will assume responsibility for all future development costs.

In January 2009 transfer and implementation of technology and process development to Roche in relation to the ongoing clinical development of TB-403 was successfully finalized. This triggered a success fee of EUR 5 million to BioInvent and ThromboGenics.

### Cancer (BI-505)

The drug candidate BI-505 is a human antibody that targets the adhesion protein ICAM-1 (also called CD54). In tumour cells the expression of ICAM-1 is elevated and it is therefore a candidate for being a suitable target protein for a therapeutic antibody. In addition to inducing apoptosis the antibody also provides important immuno-effector functions that help to kill tumour cells. BI-505 has in different animal models proved to be very effective at killing tumours and more effective than existing drugs.

BioInvent's intention is, in an initial stage, to treat patients with multiple myeloma. Other forms of hematologic cancer may also become relevant as indications. The possibility of treating ICAM-1 expressing solid tumours will also be examined further in additional preclinical trials. The number of newly diagnosed patients with multiple myeloma is more than 40,000 per year and the number of newly diagnosed patients with blood cancer is more than 200,000 per year.

BI-505 has been granted orphan drug designation in the United States and Europe for the indication of multiple myeloma. This status gives BI-505 possibility for market exclusivity for treatment of multiple myeloma with an antibody against ICAM-1 in these markets for 10 years after marketing approval is obtained.

An application to initiate phase I trials for the indication of multiple myeloma was submitted to the US Food and Drug Administration in June.

## **Research projects**

BioInvent is running a number of projects in the research phase i.e. the stage prior to selection of a Candidate Drug. The company's research portfolio currently includes projects mainly within the areas of cancer and inflammation. The research in the cancer field is aimed at additional product candidates that will impede undesirable vessel growth and thus the blood supply to tumours, as well as at apoptotic antibodies that kill tumour cells. BI-505 is one result of the apoptosis programme.

The company is also conducting research and development on antibody-based drugs on behalf of external partners. One such partner is Bayer HealthCare, the agreement allows for up to 14 antibody products to be developed. As well as undisclosed license fees and research funding, BioInvent will receive milestone payments and royalties on sales of any products commercialized.

## **Revenues and result**

Net revenues for the January – June period amounted to SEK 47.1 million (211.8). Reported net revenues include BioInvent's share, SEK 21.7 million, of the first milestone payment for TB-403. The milestone payment is for the successful technology transfer within the collaboration with Roche. BioInvent's share of the initial installment from Roche for TB-403, SEK 187.6 million is included in its entirety in reported net revenues for the second quarter 2008. Net revenues for the April – June period amounted to SEK 10.3 million (195.6).

The Company's total costs for the January – June period amounted to SEK 137.7 million (121.4). Operating costs are divided between external costs of SEK 86.9 million (76.2), personnel costs of SEK 45.2 million (39.8) and depreciation of SEK 5.6 million (5.4). Costs for toxicology studies and clinical studies, SEK 51 million, comprise the largest share of external costs. External costs have been reduced with research funding of SEK 10 million from development partners to cover their share of BioInvent's internal development costs.

Research and development costs for January – June amounted to SEK 120.6 million (106.0). Depreciation according to plan reduced the operating result for the period by SEK 5.6 million (5.4), of which depreciation of intangible fixed assets amounts to SEK 2.8 million (2.9).

The loss after tax for January – June amounted to SEK -88.2 million (93.8). The loss after tax for April - June amounted to SEK -53.5 million (133.7). The net financial items, January – June, amounted to SEK 2.4 million (3.4). Earnings per share after tax, January – June, amounted to SEK -1.59 (1.68).

## **Financial position and cash flow**

As of 30 June 2009, the Group's current investments together with cash and bank amounted to SEK 150.5 million (121.7). The cash flow from current operations and investment activities for January – June amounted to SEK -61.9 million (-95.2). The improvement in cash flow is due to more capital tied up in short-term receivables (mainly accounts receivable) corresponding period previous year.

The shareholders' equity amounted to SEK 143.5 million (308.0) at the end of the period. The Company's share capital was SEK 27.8 million. The equity/assets ratio at the end of the period was 69.5 (83.0) per cent. Shareholders' equity per share amounted to SEK 2.58 SEK (5.53). The Group had no interest-bearing liabilities.

## **Investments**

Investments in tangible fixed assets amounted to SEK 0.6 million (3.7). No investments were made in intangible assets during the period.

## Organisation

As of 30 June 2009, BioInvent had 105 (102) employees. 90 (87) of these work in research and development.

## Employee incentive program

The annual general meeting on 14 April 2008 resolved to adopt an incentive program comprising a maximum of 1,450,000 employee options (Sw. personaloptioner) and to issue 1,920,090 warrants for the subsidiary BioInvent Finans AB, free of charge, to secure the company's commitment under the incentive program and to cover the company's associated social security contributions. BioInvent Finans AB has subscribed all the warrants. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 513,750 employee options took place during 2008 and 2009. Extra allotment of 69,750 employee options took place in February 2009.

The annual general meeting on 21 April 2009 resolved to adopt an amendment to the existing employee options program 2008/2012, resolved by the AGM 2008. The amendment program comprise a maximum of 240 250 employee options, directed to the employees of the Company, entitling the holder to subscribe for new shares. Each employee option entitles the holder to subscribe to a new share at a subscription price of SEK 26.84. A basic allocation of 22,500 employee options took place in June 2009.

## Risk factors

The Company's operations are associated with risks related to factors such as drug development, competition, collaboration with partners, technology development, patents, capital requirements, currency and interest rates. The aforementioned risks summarize the factors of significance for BioInvent and thus an investment in the BioInvent share.

## Accounting principles

For the group's part this interim report is prepared according to IAS 34, Interim Financial Reporting, and the Annual Accounts Act and for the parent company's part according to the Annual Accounts Act and the Swedish Financial Reporting Board's Recommendation RFR 2.2, Accounting for legal entities. The accounting principles applied are consistent with those used when preparing the most recent Annual Report with the following exceptions due to new or revised standards, interpretations and improvements adopted by the EU and which came into force on 1 January 2009: IFRS 8 Operating segments, revised IAS 1 Presentation of financial statements, IAS 23 Borrowing costs, IAS 32 Financial instruments, amendment to IAS 27 changing the rules for recognition of dividend revenue from subsidiaries, associates, and jointly controlled entities, and IFRIC 13 Customer Loyalty Programmes. The only change that affects the Group and the parent company is revised IAS 1 Presentation of financial statements. This standard divides changes in shareholders' equity resulting from transactions with owners and other changes. Reporting of changes in equity will only include details relating to owner-related transactions. Non-owner changes in equity are presented on a separate line in changes in equity. In addition, the standard concept "Statement of comprehensive income" is being introduced, which shows all recognised income and expense items either in a single statement, or in two consecutive statements. The Group has chosen to present the Statement of comprehensive income in a single statement.

## Upcoming financial reports

BioInvent will present the following financial reports:

Interim reports	15 October 2009
Financial statement for 2009	17 February 2010

## Contact

Any questions regarding this report will be answered by:

### **BioInvent International AB (publ.)**

Svein Mathisen, President & CEO, tel.+46 (0)46 286 85 67, mobile +46 (0)708 97 82 13  
Cristina Glad, Executive Vice President, tel. +46 (0)46 286 85 51, mobile +46 (0)708 16 85 70.

### **College Hill**

Holly Griffiths, Sue Charles and John McIntyre, tel. +44 (0)20 7457 2020, [bioinvent@collegehill.com](mailto:bioinvent@collegehill.com)

The report is also available at [www.bioinvent.com](http://www.bioinvent.com)

## Consolidated statement of comprehensive income in brief for the Group (SEK thousands)

	3 MONTHS 2009 April.-June	3 MONTHS 2008 April.-June	6 MONTHS 2009 Jan.-June	6 MONTHS 2008 Jan.-June	12 MONTHS 2008 Jan.-Dec.
Net revenues	10,274	195,648	47,123	211,832	252,138
<i>Operating costs</i>					
Research and development costs	-56,819	-54,862	-120,590	-105,958	-215,434
Sales and administrative costs	-8,353	-8,645	-17,079	-15,585	-30,882
Other operating revenues and costs	582	-78	-110	93	749
	<u>-64,590</u>	<u>-63,585</u>	<u>-137,779</u>	<u>-121,450</u>	<u>-245,567</u>
<b>Operating profit/loss</b>	<b>-54,316</b>	<b>132,063</b>	<b>-90,656</b>	<b>90,382</b>	<b>6,571</b>
Profit/loss from financial investments	814	1,620	2,429	3,399	9,680
<b>Profit/loss after financial items</b>	<b>-53,502</b>	<b>133,683</b>	<b>-88,227</b>	<b>93,781</b>	<b>16,251</b>
Tax	-	-	-	-	-
<b>Profit/loss</b>	<b>-53,502</b>	<b>133,683</b>	<b>-88,227</b>	<b>93,781</b>	<b>16,251</b>
<i>Other comprehensive income</i>					
Changes in reserve, actual value	-93	101	-149	19	313
<b>Comprehensive income</b>	<b>-53,595</b>	<b>133,784</b>	<b>-88,376</b>	<b>93,800</b>	<b>16,564</b>
Profit/loss pertaining to the parent company's shareholders	-53,595	133,784	-88,376	93,800	16,564
Earnings per share, SEK					
Before dilution	-0.96	2.40	-1.59	1.68	0.29
After dilution	-0.96	2.40	-1.59	1.68	0.29

## Consolidated statement of financial position in brief for the Group (SEK thousands)

	2009 30 June	2008 30 June	2008 31 Dec.
<b>Assets</b>			
<b>Fixed assets</b>			
Intangible fixed assets	9,570	9,668	12,384
Tangible fixed assets	14,199	15,451	16,427
<b>Current assets</b>			
Inventories etc.	2,058	8,399	2,304
Current receivables	30,088	215,654	51,852
Current investments	125,874	107,834	196,066
Cash and bank	24,669	13,864	16,394
<b>Total assets</b>	<b>206,458</b>	<b>370,870</b>	<b>295,427</b>
<b>Shareholders' equity and liabilities</b>			
Shareholders' equity	143,503	307,976	231,298
Current liabilities	62,955	62,894	64,129
<b>Total shareholders' equity and liabilities</b>	<b>206,458</b>	<b>370,870</b>	<b>295,427</b>

## Statement of changes in equity for the Group (SEK thousands)

	2009 April.-June	2008 April.-June	2009 Jan.-June	2008 Jan.-June	2008 Jan.-Dec.
<b>Opening balance</b>	<b>196,791</b>	<b>174,134</b>	<b>231,298</b>	<b>214,118</b>	<b>214,118</b>
Effect of employee incentive program	307	58	581	58	616
Comprehensive income	-53,595	133,784	-88,376	93,800	16,564
<b>Closing balance</b>	<b>143,503</b>	<b>307,976</b>	<b>143,503</b>	<b>307,976</b>	<b>231,298</b>
Shareholders' equity pertaining to the parent company's shareholders	143,503	307,976	143,503	307,976	231,298

The share capital as of 30 June 2009 consists of 55,660,889 shares and the share's ratio value is 0.5.

## Consolidated statement of cash flows in brief for the Group (SEK thousands)

	2009 April.-June	2008 April.-June	2009 Jan.-June	2008 Jan.-June	2008 Jan.-Dec.
<b>Current operations</b>					
Operating profit/loss	-54,316	132,063	-90,656	90,382	6,571
Depreciation	2,704	2,709	5,649	5,338	11,543
Interest received and paid	<u>776</u>	<u>624</u>	<u>3,638</u>	<u>3,188</u>	<u>9,361</u>
<b>Cash flow from current operations before changes in working capital</b>	<b>-50,836</b>	<b>135,396</b>	<b>-81,369</b>	<b>98,908</b>	<b>27,475</b>
Changes in working capital	<u>9,628</u>	<u>-169,221</u>	<u>20,058</u>	<u>-190,318</u>	<u>-18,227</u>
<b>Cash flow from current operations</b>	<b>-41,208</b>	<b>-33,825</b>	<b>-61,311</b>	<b>-91,410</b>	<b>9,248</b>
<b>Investment activities</b>					
Acquisition of intangible fixed assets	-	-	-	-	-6,001
Acquisition of tangible fixed assets	<u>-588</u>	<u>-2,161</u>	<u>-606</u>	<u>-3,743</u>	<u>-7,638</u>
<b>Cash flow from investment activities</b>	<b>-588</b>	<b>-2,161</b>	<b>-606</b>	<b>-3,743</b>	<b>-13,639</b>
<b>Cash flow from current operations and investment activities</b>	<b>-41,796</b>	<b>-35,986</b>	<b>-61,917</b>	<b>-95,153</b>	<b>-4,391</b>
<b>Financing activities</b>	-	-	-	-	-
<b>Changes in current investments**</b>	<b>19,566</b>	<b>34,369</b>	<b>62,275</b>	<b>46,531</b>	<b>-6,815</b>
<b>Change in liquid funds</b>	<b>-22,230</b>	<b>-1,617</b>	<b>358</b>	<b>-48,622</b>	<b>-11,206</b>
Opening liquid funds	<u>73,868</u>	<u>15,481</u>	<u>51,280</u>	<u>62,486</u>	<u>62,486</u>
<b>Liquid funds at end of period</b>	<b>51,638</b>	<b>13,864</b>	<b>51,638</b>	<b>13,864</b>	<b>51,280</b>
<b>Liquid funds, specification:</b>					
Current investments that constitute liquid funds*	26,969	-	26,969	-	34,886
Cash and bank	<u>24,669</u>	<u>13,864</u>	<u>24,669</u>	<u>13,864</u>	<u>16,394</u>
	<b>51,638</b>	<b>13,864</b>	<b>51,638</b>	<b>13,864</b>	<b>51,280</b>
Current investments**	<u>98,905</u>	<u>107,834</u>	<u>98,905</u>	<u>107,834</u>	<u>161,180</u>
	<b>150,543</b>	<b>121,698</b>	<b>150,543</b>	<b>121,698</b>	<b>212,460</b>

\*Duration less than 3 months

\*\*Duration more than 3 months

## Key financial ratios for the Group

	2009 30 June	2008 30 June	2008 31 Dec.
Shareholders' equity per share at end of period, SEK			
Before dilution	2.58	5.53	4.15
After dilution	2.58	5.53	4.15
Number of shares at end of period			
Before dilution (thousands)	55,661	55,661	55,661
After dilution (thousands)	55,661	55,661	55,661
Equity/assets ratio, %	69.5	83.0	78.3
Number of employees at end of period	105	102	103

## Consolidated income statement in brief for the Parent Company (SEK thousands)

	6 MONTHS 2009 Jan.-June	6 MONTHS 2008 Jan.-June	12 MONTHS 2008 Jan.-Dec.
Net revenues	47,123	211,832	252,138
<i>Operating costs</i>			
Research and development costs	-120,122	-105,911	-214,933
Sales and administrative costs	-16,966	-15,574	-30,767
Other operating revenues and costs	-110	93	749
	<u>-137,198</u>	<u>-121,392</u>	<u>-244,951</u>
<b>Operating profit/loss</b>	<b>-90,075</b>	<b>90,440</b>	<b>7,187</b>
Profit/loss from financial investments	2,429	3,400	9,680
<b>Profit/loss after financial items</b>	<b>-87,646</b>	<b>93,840</b>	<b>16,867</b>
Tax	-	-	-
<b>Profit/loss</b>	<b>-87,646</b>	<b>93,840</b>	<b>16,867</b>

## Consolidated balance sheet in brief for the Parent Company (SEK thousands)

	2009 30 June	2008 30 June	2008 31 Dec.
<b>Assets</b>			
<b>Fixed assets</b>			
Intangible fixed assets	9,570	9,668	12,384
Tangible fixed assets	14,199	15,451	16,427
Financial fixed assets	100	100	100
<b>Current assets</b>			
Inventories etc.	2,058	8,399	2,304
Current receivables	30,088	214,524	51,852
Current investments	125,827	107,932	195,870
Cash and bank	24,669	13,864	16,394
<b>Total assets</b>	<b>206,511</b>	<b>369,938</b>	<b>295,331</b>
<b>Shareholders' equity and liabilities</b>			
Shareholders' equity	143,469	308,088	231,115
Current liabilities	63,042	61,850	64,216
<b>Total shareholders' equity and liabilities</b>	<b>206,511</b>	<b>369,938</b>	<b>295,331</b>

The board of directors and the CEO hereby ensure that this interim report for the period 1 January 2009 – 30 June 2009 provides a fair overview of the operations, financial position and performance of the Company and the Group and describes the material risks and uncertainty factors faced by the Company and the companies included in the Group.

Lund, 15 July 2009

Karl Olof Borg  
Chairman of the Board

Carl Borrebaeck

Lars Henriksson

Lars Ingelmark

Elisabeth Lindner

Ulrika T Mattson

Björn Nilsson

Kentth Petersson

Svein Mathisen  
President and CEO

## Review report

### *Introduction*

We have reviewed the summarised interim financial information for BioInvent International AB (publ) for the period 1 January 2009 – 30 June 2009. The board of directors and the CEO are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

### *Scope of review*

We conducted our review in accordance with the Standard on Review Engagements SÖG 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing in Sweden RS and other generally accepted auditing practices. The procedures performed in a review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit. Therefore, the conclusion expressed based on a review does not give the same level of assurance as a conclusion expressed based on an audit.

### *Conclusion*

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, for the group's part according to IAS 34 and the Annual Accounts Act and for the parent company's part according to the Annual Accounts Act.

Lund, 15 juli 2009  
ERNST & YOUNG AB

Johan Thuresson  
Authorised Public Accountant

## **BioInvent International AB (publ.)**

Co. reg. no. 556537-7263  
Address: Sölvegatan 41, 223 70 Lund  
Tel.: +46 (0)46 286 85 50  
[info@bioinvent.com](mailto:info@bioinvent.com)

## **Legal disclaimer**

This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this press release.

*Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. CET, on 15 July, 2009.*